View source for DNX-2401 adenovirus



{{TreatmentInfo
|drug_name=DNX-2401 adenovirus
|category=Oncolytic virotherapy
|book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO
trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.
Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented
at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma
patients had been treated, with no adverse events attributable to the virus being reported.
3 of 25 patients responded to the treatment with complete, durable responses of 42, 32,
and 29 months so far. These three complete responders had vigorous immune responses,
with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance
for type-1 anti-tumor immune responses.
}}